Commitments and Contingencies - Additional Information (Details) $ in Thousands |
3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|
|
Aug. 04, 2023
shares
|
Jun. 30, 2025
USD ($)
|
Jun. 30, 2024
USD ($)
|
Jun. 30, 2025
USD ($)
Action
|
Jun. 30, 2024
USD ($)
|
|
| Loss Contingencies [Line Items] | |||||
| Other income related to subleases | $ | $ 4,708 | $ 235 | $ 5,493 | $ 228 | |
| Number of actions filed | Action | 2 | ||||
| Legal proceedings allegations | The Complaints allege that the defendants filed or caused to be filed a materially incomplete and misleading registration statement with the SEC and asserts claims under New York common law for negligent misrepresentation and concealment and negligence. In addition, the Company and its board of directors have received five additional demands from purported stockholders seeking additional disclosures in the registration statement (collectively, the “Demands”). | ||||
| Smith v. Ikena Oncology, Inc. | |||||
| Loss Contingencies [Line Items] | |||||
| Lawsuit filing date | Jun. 12, 2025 | ||||
| Kent v. Ikena Oncology, Inc. | |||||
| Loss Contingencies [Line Items] | |||||
| Lawsuit filing date | Jun. 13, 2025 | ||||
| Pionyr Immunotherapeutics, Inc | |||||
| Loss Contingencies [Line Items] | |||||
| Percentage of net proceeds from potential monetization of legacy programs receivable | 50.00% | ||||
| Business acquisition, contingent value right received for each share | shares | 1 | ||||
| Contingent value rights period | 2 years | ||||